Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults.
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.
Supplementary Figure S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Supplementary Table S1 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Data from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Supplementary Table S2 from Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children’s Oncology Group
Germline Cancer Predisposition Results From the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Performance of Two-Phase Designs for the Time-to-Event Outcome and a Case Study Assessing the Relapse Risk Associated With B-ALL Subtypes.
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia
Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Cancer Research for 35 Years.
Chi SN, Yi JS, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey BD, Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju A, Mhlanga JC, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV, Janeway KA, Seibel NL, Parsons DW. Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterat
— 2023cited by 0position: selected
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
Gadd S, Huff V, Skol AD, Renfro LA, Fernandez CV, Mullen EA, Jones CD, Hoadley KA, Yap KL, Ramirez NC, Aris S, Phung QH, Perlman EJ. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study. Cell Rep Med. 2022 Jun 21; 3: 100644.
— 2022cited by 0position: selected
Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
McCall SJ, Branton PA, Blanc VM, Dry SM, Gastier-Foster JM, Harrison JH, Jewell SD, Dash RC, Obeng RC, Rose J, Mateski DL, Liubinskas A, Robb JA, Ramirez NC, Shea K. The College of American Pathologists Biorepository Accreditation Program: Results from the First 5 Years. Biopreserv Biobank. 2018 Feb
— 2018cited by 0position: selected
Furuta K, Allocca CM, Schacter B, Bledsoe MJ, Ramirez NC. Standardization and Innovation in Paving a Path to a Better Future: An Update of Activities in ISO/TC276/WG2 Biobanks and Bioresources. Biopreserv Biobank. 2018 Feb; 16: 23-27.
— 2018cited by 0position: selected
Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, Bernards SS, Casadei S, Burger RA, Tewari KS, Backes F, Mannel RS, Glaser G, Bailey C, Rubin S, Soper J, Lankes HA, Ramirez NC, King MC, Birrer MJ, Swisher EM. Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinom
— 2018cited by 0position: selected
Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ. An NRG Oncology/GOG study of molecular classification for risk predicti
— 2018cited by 0position: selected
Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study
Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
Inherited Mutations in Women With Ovarian Carcinoma
The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study
Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma